

# **Enrolling Patients in KaryForward Patient Support**

#### **OPTION 1**

To enroll patients online via Docusign, visit KaryForward.com/HCP



| •                                      | enclosed enrollment form. All fields are required. Incomplete fields rocessing delays.   |
|--|--|
| Ensure all se                          | ections of the enrollment form are fully completed.  |
| If requesting                          | g a QuickStart, prescriber's signature/date is required in section 7.  |
| Prescriber's                           | signature/date is required for prescription in Section 8.  |
| lf necessary plea<br>your state's requ | ase attach a separate prescription for sections 7 and 8 to meet uirement.  |
| Prescriber's                           | signature/date is required in Section 10.  |
| If patient is                          | egal representative's signature/date is required in section 11. not present to sign consent section 11, they may use the e-consent ryForward.com |
| , .                                    | for the Patient Assistance Program, patient or legal representative's ate is required in section 12.   |
| If patient ha                          | as insurance, if possible, include a copy of both sides of patient's ards.   |



**KaryForward Options\*** (select any of interest)

## **Enrollment Form**

Page 1 of 4

Be sure to fill out all sections of this form. All fields are required. Incomplete fields may cause processing delays.

| Insurance Verification                  | Financial Assistance  | Support and Resources   |  |  |  |  |
|---|---|---|--|--|--|--|
| Benefit Investigation,                  | Patient Assistance Program (PAP)  | O Nurse Case Manager  |  |  |  |  |
| Prior Authorization,                    | Copay Program   | <ul> <li>Independent Third-Party Copay Assistance</li> <li>*All programs and support are subject to eligibility requirements</li> </ul> |  |  |  |  |
| Appeal Assistance                       | (patients may also be enrolled directly online at: KaryForward.com/HCP) |   |  |  |  |  |
|   | offilline at. Karyrof ward.com/ncr/                                     |   |  |  |  |  |
| 2 Healthcare Profe                      | ssional/Facility Information  |   |  |  |  |  |
| Prescriber Name (first last):           |   | Facility Name:  |  |  |  |  |
| Prescriber Title:                       |   | Mailing Address:  |  |  |  |  |
| NPI #:                                  |   | City: State: Zip:   |  |  |  |  |
| DEA #:                                  |   | Office Contact Name:  |  |  |  |  |
| Tax ID #:                               |   | Office Contact Email:   |  |  |  |  |
| PTAN #:                                 |   | Office Phone: Fax:  |  |  |  |  |
| 3 Patient Informat                      | ion   |   |  |  |  |  |
| Patient Name (first last):              |   | Gender: OMale Female Date of Birth:///  |  |  |  |  |
| Mailing Address:                        |   | Home Phone: Cell Phone:   |  |  |  |  |
| City:                                   | State: Zip:   | Email:  |  |  |  |  |
| Shipping Address:                       | (if different than mailing)   | Preferred Contact: O Home Phone Cell Phone Email  |  |  |  |  |
|   | (if different than mailing) State: Zip:                                 | Best Time to Contact: O Day (8am–5pm ET) Night (after 5pm ET)   |  |  |  |  |
| _                                       |   | best fille to contact. Say (oall spill 21)  |  |  |  |  |
| 4 Caregiver Inform                      | ation (optional)  |   |  |  |  |  |
| Caregiver Name:                         |   | Caregiver Phone:  |  |  |  |  |
| Contact Caregiver instead of            | Patient? O Yes O No   | Best Time to Contact: O Day (8am–5pm ET) Night (after 5pm ET)   |  |  |  |  |
| 5 Insurance Inform                      | nation (if possible, please include a copy of b                         | ooth sides of patient's insurance cards)  |  |  |  |  |
| Patient is insured by: (check           | all that apply)   | Primary Insurance   |  |  |  |  |
| O Commercial/Private Insura             | ance  | Provider:   |  |  |  |  |
| O Medicare Part A (Hospital)            |   | Provider Phone:   |  |  |  |  |
| Medicare Part B (Medical)               |   | Cardholder Name:  |  |  |  |  |
| Medicare Part D (Prescription)          |   | Member ID/Policy #:   |  |  |  |  |
| Medicare Advantage                      |   | Group #:  |  |  |  |  |
| Medicaid                                |   | Prescription Insurance  |  |  |  |  |
| VA or Military                          | 6 A4 B B  | Provider:   |  |  |  |  |
| State Assistance Program for Medication |   | Provider Phone:   |  |  |  |  |
|   |   | Cardholder Name:  |  |  |  |  |
| None                                    |   | Member ID/Policy #:   |  |  |  |  |
| Medicare ID:                            |   | Rx BIN #: Rx PCN #:   |  |  |  |  |











## **Enrollment Form**

Page 2 of 4

Be sure to fill out all sections of this form. All fields are required. Incomplete fields may cause processing delays.

| 6 Preferred Special  | ty Pharmacy (select one)                             |                                       |  |  |  |  |  |
|--|--|---------------------------------------|--|--|--|--|--|
| O In-office dispensing site  | Onco 360 Biologics, Inc. No                          | o preference                          |  |  |  |  |  |
| 7 QuickStart Program (optional - complete this section only for QuickStart prescription) |  |                                       |  |  |  |  |  |
| If necessary please attach a s   | eparate prescription to meet your state's requi      | rement.                               |  |  |  |  |  |
| Patient Name:  |  | Date of Birth: / /                    | <u></u>  |  |  |  |  |
| Rx for XPOVIO® (selinexo   | r)   |                                       |  |  |  |  |  |
| Dose prescribed (mg weekly)  | START DATE:  | //_                                   |  |  |  |  |  |
| QTY of tablets (7 day supply)  | NOTE, ALOVIO (30                                     | elinexor) will be delivered to the ma |  |  |  |  |  |
| See table in Section 8 for addition  |  | different shipping address is provide | ded.   |  |  |  |  |
|  |  |                                       |  |  |  |  |  |
| Prescriber Name (print):   |  |                                       |  |  |  |  |  |
| SIGN HERE Prescriber Sign  | nature:  |                                       | / Date://  |  |  |  |  |
| 8 PAP Prescription   | Information  |                                       |  |  |  |  |  |
|  | eparate prescription to meet your state's requi      | rement.                               |  |  |  |  |  |
|  |  |                                       |  |  |  |  |  |
|  |  | / Date of biltii/                     |  |  |  |  |  |
| Rx for XPOVIO® (selinexo   | ir)  |                                       |  |  |  |  |  |
| (select only one)  | Tablets for 28 Day Supply                            | NDC                                   | <b>START DATE:</b> /   |  |  |  |  |
| 0 100 mg once weekly   | Two 50 mg tablets per blister pack (8 tablets per c  | arton) NDC 72237-103-05               | QTY of tablets   |  |  |  |  |
| 0 80 mg once weekly  | Two 40 mg tablets per blister pack (8 tablets per ca |                                       | (28 day supply):   |  |  |  |  |
| 60 mg once weekly  | One 60 mg tablets per blister pack (4 tablets per c  | ·                                     | Refills:   |  |  |  |  |
| 40 mg once weekly  | One 40 mg tablets per blister pack (4 tablets per c  | <u> </u>                              | NOTE: XPOVIO® (selinexor)                                      |  |  |  |  |
| 80 mg twice weekly   | Eight 20 mg tablets per blister pack (32 tablets per | •                                     | will be delivered to the mailing address in Section 3 unless a |  |  |  |  |
| 60 mg twice weekly   | Six 20 mg tablet per blister pack (24 tablets per ca | <u> </u>                              | different shipping address                                     |  |  |  |  |
| 40 mg twice weekly   | Two 20 mg tablet per blister pack (8 tablets per ca  | rton) NDC 72237-102-06                | is provided.   |  |  |  |  |
|  |  |                                       |  |  |  |  |  |
| Prescriber Name (print):   |  |                                       |  |  |  |  |  |
| Trescriber Nume (print).   |  |                                       |  |  |  |  |  |
| " -  | nature:  |                                       | Date://  |  |  |  |  |
| " -  |  |                                       | /  |  |  |  |  |
| 9 Clinical Informat  | ion  |                                       | Date: / /  |  |  |  |  |
| 9 Clinical Informat Patient Diagnosis:   | ion  | ICD-10 Code:                          |  |  |  |  |  |
| 9 Clinical Informat Patient Diagnosis: Prior Treatment:                                  | ion  | ICD-10 Code:Current Line of Therapy:  | Date:/   |  |  |  |  |
| 9 Clinical Informat Patient Diagnosis: Prior Treatment:                                  | ion  | ICD-10 Code:Current Line of Therapy:  | Date:/   |  |  |  |  |
| 9 Clinical Informat Patient Diagnosis: Prior Treatment:                                  | ion  | ICD-10 Code:Current Line of Therapy:  | Date:/   |  |  |  |  |











### **Enrollment Form**

Page 3 of 4

Be sure to fill out all sections of this form. All fields are required. Incomplete fields may cause processing delays.

#### 10 Healthcare Professional Certification

By signing below, I hereby represent, covenant, and certify as follows:

- (1) The above therapy (or medicine) is medically necessary;
- (2) I have obtained from my patient his or her consent and any required written authorization as required by HIPAA and other federal or state laws to release to KaryForward (Karyopharm Therapeutics Patient Access and Support Services) and its representatives/agents all patient information needed for this application, including, without limitation, my patient's financial and medical information;
- (3) I understand that KaryForward and its representatives/agents will use this information to assess the patient's eligibility for participation in KaryForward;
- (4) I have not received, nor will I seek or accept reimbursement from any federal, state, or private payers for any drug provided for my patient by the Patient Assistance Program (PAP);
- (5) I have not received, nor will I seek or accept payment from my patient for any co-insurance amount paid for by the XPOVIO® Copay Program for a Karyopharm Therapeutics product;
- (6) I understand that if my patient's insurance or financial status changes, the patient may no longer be eligible under this program. I will notify KaryForward if I become aware of any such changes;
- (7) I understand that I am under no obligation to prescribe any Karyopharm Therapeutics drug and I have not received and will not receive any benefit from Karyopharm Therapeutics for prescribing a Karyopharm Therapeutics drug;
- (8) the information contained in this form is complete and accurate to the best of my knowledge; and
- (9) I will notify KaryForward of any errors regarding the foregoing, and will make every effort to correct those errors.

| HCP Name (print):                           |       |   |   |
|---|-------|---|---|
| SIGN HERE HCP Signature (no stamps please): | Date: | / | / |













### **Enrollment Form**

Page 4 of 4

Be sure to fill out all sections of this form. All fields are required. Incomplete fields may cause processing delays.

Patient e-consent in English is available online at **KaryForward.com**. You may also download patient consent forms for Spanish or Chinese speaking patients to replace sections 11 and 12. Return all completed pages of this enrollment form with signed patient consent.

#### 11 Patient Consent

I hereby authorize my healthcare professionals, my health insurance company, and my pharmacy to disclose my protected health information (PHI) including, but not limited to, my name, address, telephone number, medical records, health insurance coverage, and financial information to KaryForward and its agents. I understand that once my health information has been disclosed to KaryForward, it could be subject to redisclosure and that federal privacy laws may no longer protect the information.

I hereby authorize KaryForward and its agents (1) To contact me, or the person legally authorized to sign on my behalf, by phone or mail, (2) to contact my insurance company on my behalf to verify my coverage for XPOVIO® (selinexor), (3) to determine my eligibility for enrollment in the XPOVIO® Copay Program and for enrollment in the Patient Assistance Program (PAP), including verification of my financial information, (4) to determine my eligibility for enrollment in the Dose Exchange Program, (5) Provide me with information regarding any independent third-party foundation or alternate sources of funding or coverage that may be available to provide assistance with out-of-pocket expenses, (6) Coordinate my treatment with my healthcare professionals and specialty pharmacy, and (7) Send me materials regarding products, services, or other information that may be of interest to me.

I understand that if I refuse to sign this authorization, it will not affect my treatment by my healthcare professionals, or my payment, enrollment, or eligibility for benefits from my health plan. However, if I refuse to sign this authorization, or sign and then withdraw my authorization at a later date, it may affect my ability to participate in KaryForward. If I do not withdraw authorization, it will remain valid for 3 years (or at such lesser time as state law may require). I understand I am entitled to receive a copy of this authorization.

| Patient or Legal Representative Name (print):   |             |           |       |  |
|---|-------------|-----------|-------|--|
| SIGN HERE Patient or Legal Representative Signature:  | Date:       | _/        | _/    |  |
|   |             |           |       |  |
| Patient Financial Consent (only required if applying for Patient Assistance Program)  |             |           |       |  |
| Gross Annual Household Income: No. of household members dependent on inc  | ome (includ | le applic | ant): |  |
| Income source(s) (check all that apply): O Job O Family O Public Assistance O SSI/SSDI O Other:   |             |           |       |  |
| KaryForward may need additional documentation to assess program eligibility (i.e., 1040 Tax Return, SSA-1099, W-2 Formatter (i.e., 1040 Tax Return, SSA-1099, W-2 Formatter)  | n)          |           |       |  |
| Patient Acknowledgment:   |             |           |       |  |
| I understand that completing this form does not ensure my enrollment in the Patient Assistance  | e Progran   | n ("PAF   | ?").  |  |
| By signing below, I certify that the information provided is complete and accurate. I authorize Karyopharm and its service providers administering the PAP (collectively, "KaryForward") to obtain financial information from my credit profile or other financial information from Experian Income View. I understand that KaryForward needs, and I agree that KaryForward may use, this financial information to determine my financial eligibility to participate in KaryForward's Patient Assistance Program. I also agree to provide additional financial documentation in a timely manner, if so requested. |             |           |       |  |
| Patient or Legal Representative Name (print):   |             |           |       |  |
| SIGN HERE Patient or Legal Representative Signature:  | Date:       | _/        | _/    |  |







